{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:20:36Z","timestamp":1783405236396,"version":"3.54.6"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40259-026-00776-y","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:04:32Z","timestamp":1778612672000},"page":"733-745","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials"],"prefix":"10.1007","volume":"40","clinical-trial-number":[{"clinical-trial-number":"nct03518086","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03524092","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Zhihua","family":"Ran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinglei","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengdang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijuan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naizhong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7206-1847","authenticated-orcid":false,"given":"Jun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"issue":"9853","key":"776_CR1","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","volume":"380","author":"I Ord\u00e1s","year":"2012","unstructured":"Ord\u00e1s I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012;380(9853):1606\u201319.","journal-title":"Lancet"},{"issue":"3","key":"776_CR2","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384\u2013413.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"776_CR3","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1053\/j.gastro.2022.01.023","volume":"162","author":"N Krugliak Cleveland","year":"2022","unstructured":"Krugliak Cleveland N, Torres J, Rubin DT. What does disease progression look like in ulcerative colitis, and how might it be prevented? Gastroenterology. 2022;162(5):1396\u2013408.","journal-title":"Gastroenterology"},{"issue":"5","key":"776_CR4","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1053\/j.gastro.2021.08.060","volume":"162","author":"L Keefer","year":"2022","unstructured":"Keefer L, Bedell A, Norton C, Hart AL. How should pain, fatigue, and emotional wellness be incorporated into treatment goals for optimal management of inflammatory bowel disease? Gastroenterology. 2022;162(5):1439\u201351.","journal-title":"Gastroenterology"},{"issue":"Supplement_2","key":"776_CR5","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjae082","volume":"18","author":"B Caron","year":"2024","unstructured":"Caron B, Honap S, Peyrin-Biroulet L. Epidemiology of inflammatory bowel disease across the ages in the era of advanced therapies. J Crohns Colitis. 2024;18(Supplement_2):ii3\u201315.","journal-title":"J Crohns Colitis"},{"issue":"5","key":"776_CR6","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","volume":"165","author":"JD Lewis","year":"2023","unstructured":"Lewis JD, Parlett LE, Jonsson Funk ML, Brensinger C, Pate V, Wu Q, et al. Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States. Gastroenterology. 2023;165(5):1197-205.e2.","journal-title":"Gastroenterology"},{"issue":"10","key":"776_CR7","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/ueg2.12350","volume":"10","author":"S Aniwan","year":"2022","unstructured":"Aniwan S, Santiago P, Loftus EV Jr., Park SH. The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries. Unit Eur Gastroenterol J. 2022;10(10):1063\u201376.","journal-title":"Unit Eur Gastroenterol J"},{"issue":"13","key":"776_CR8","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1016\/j.cgh.2023.08.013","volume":"21","author":"L Xu","year":"2023","unstructured":"Xu L, He B, Sun Y, Li J, Shen P, Hu L, et al. Incidence of inflammatory bowel disease in urban China: a nationwide population-based study. Clin Gastroenterol Hepatol. 2023;21(13):3379-86.e29.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"776_CR9","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1002\/ueg2.12634","volume":"12","author":"J Wan","year":"2024","unstructured":"Wan J, Shen J, Zhong J, Ge W, Miao Y, Zhang X, et al. Natural course of ulcerative colitis in China: differences from the West? Unit Eur Gastroenterol J. 2024;12(9):1167\u201378.","journal-title":"Unit Eur Gastroenterol J."},{"issue":"11","key":"776_CR10","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1111\/dom.15238","volume":"25","author":"K Chen","year":"2023","unstructured":"Chen K, Shen Z, Gu W, Lyu Z, Qi X, Mu Y, et al. Prevalence of obesity and associated complications in China: a cross-sectional, real-world study in 15.8 million adults. Diabetes Obes Metab. 2023;25(11):3390\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"14","key":"776_CR11","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1097\/CM9.0000000000003221","volume":"137","author":"Inflammatory Bowel Disease Group","year":"2024","unstructured":"Inflammatory Bowel Disease Group. 2023 Chinese national clinical practice guideline on diagnosis and management of ulcerative colitis. Chin Med J (Engl). 2024;137(14):1642\u20136.","journal-title":"Chin Med J (Engl)"},{"key":"776_CR12","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000995776.43269.ce","author":"DT Rubin","year":"2023","unstructured":"Rubin DT, Barnes EL, Shah S, Ahmad HA, Gazis D, Morris HL, et al. S10\u2003Outcomes of early versus delayed advanced therapy among patients with moderate ulcerative colitis in the United States: TARGET-IBD. Am J Gastroenterol. 2023. https:\/\/doi.org\/10.14309\/01.ajg.0000995776.43269.ce.","journal-title":"Am J Gastroenterol"},{"key":"776_CR13","doi-asserted-by":"crossref","unstructured":"Krugliak Cleveland N, Candela N, Carter JA, Kuharic M, Qian J, Tang Z, et al. Real-world treatment outcomes associated with early versus delayed vedolizumab initiation in patients with ulcerative colitis. Crohns Colitis 360. 2024;6(4):otae061.","DOI":"10.1093\/crocol\/otae061"},{"issue":"1","key":"776_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s43556-024-00207-w","volume":"5","author":"Y Liang","year":"2024","unstructured":"Liang Y, Li Y, Lee C, Yu Z, Chen C, Liang C. Ulcerative colitis: molecular insights and intervention therapy. Mol Biomed. 2024;5(1):42.","journal-title":"Mol Biomed"},{"key":"776_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.897936","volume":"9","author":"J Marsal","year":"2022","unstructured":"Marsal J, Barreiro-de Acosta M, Blumenstein I, Cappello M, Bazin T, Sebastian S. Management of non-response and loss of response to Anti-tumor Necrosis Factor therapy in inflammatory bowel disease. Front Med. 2022;9:897936.","journal-title":"Front Med"},{"key":"776_CR16","doi-asserted-by":"publisher","first-page":"175628482110640","DOI":"10.1177\/17562848211064004","volume":"14","author":"LA Lucaciu","year":"2021","unstructured":"Lucaciu LA, Constantine-Cooke N, Plevris N, Siakavellas S, Derikx L, Jones GR, et al. Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2021;14:17562848211064004.","journal-title":"Therap Adv Gastroenterol."},{"issue":"5","key":"776_CR17","doi-asserted-by":"publisher","first-page":"861","DOI":"10.14309\/ajg.0000000000002129","volume":"118","author":"C Ma","year":"2023","unstructured":"Ma C, Panaccione R, Xiao Y, Khandelwal Y, Murthy SK, Wong ECL, et al. REMIT-UC: real-world effectiveness and safety of tofacitinib for moderate-to-severely active ulcerative colitis: a Canadian IBD Research Consortium Multicenter National Cohort Study. Am J Gastroenterol. 2023;118(5):861\u201371.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"776_CR18","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1093\/ibd\/izac200","volume":"29","author":"EHJ Savelkoul","year":"2023","unstructured":"Savelkoul EHJ, Thomas PWA, Derikx L, den Broeder N, R\u00f6mkens TEH, Hoentjen F. Systematic review and meta-analysis: loss of response and need for dose escalation of Infliximab and Adalimumab in ulcerative colitis. Inflamm Bowel Dis. 2023;29(10):1633\u201347.","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"776_CR19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","volume":"20","author":"B Verstockt","year":"2023","unstructured":"Verstockt B, Salas A, Sands BE, Abraham C, Leibovitzh H, Neurath MF, et al. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2023;20(7):433\u201346.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"26","key":"776_CR20","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D'Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388(26):2444\u201355.","journal-title":"N Engl J Med"},{"issue":"1","key":"776_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s41687-022-00439-w","volume":"6","author":"MC Dubinsky","year":"2022","unstructured":"Dubinsky MC, Irving PM, Panaccione R, Naegeli AN, Potts-Bleakman A, Arora V, et al. Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults. J Patient-Rep Outcomes. 2022;6(1):31.","journal-title":"J Patient-Rep Outcomes"},{"key":"776_CR22","unstructured":"U.S. Food and Drug Administration (FDA). Ulcerative colitis: developing drugs for treatment guidance for industry 2022 https:\/\/www.fda.gov\/media\/158016\/download."},{"issue":"5","key":"776_CR23","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, D\u2019Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160(5):1570\u201383.","journal-title":"Gastroenterology"},{"key":"776_CR24","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003463","author":"DT Rubin","year":"2025","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. ACG clinical guideline update: ulcerative colitis in adults. Am J Gastroenterol. 2025. https:\/\/doi.org\/10.14309\/ajg.0000000000003463.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"776_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2\u201317.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"776_CR26","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/mi.2012.24","volume":"5","author":"BM Fournier","year":"2012","unstructured":"Fournier BM, Parkos CA. The role of neutrophils during intestinal inflammation. Mucosal Immunol. 2012;5(4):354\u201366.","journal-title":"Mucosal Immunol"},{"issue":"1","key":"776_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/ecco-jcc\/jjad130","volume":"18","author":"S Schreiber","year":"2024","unstructured":"Schreiber S, Danese S, Dignass A, Dom\u00e8nech E, Fantini MC, Ferrante M, et al. Defining comprehensive disease control for use as a treatment target for ulcerative colitis in clinical practice: International Delphi Consensus recommendations. J Crohns Colitis. 2024;18(1):91\u2013105.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"776_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s41687-019-0154-x","volume":"3","author":"L Newton","year":"2019","unstructured":"Newton L, Randall JA, Hunter T, Keith S, Symonds T, Secrest RJ, et al. A qualitative study exploring the health-related quality of life and symptomatic experiences of adults and adolescents with ulcerative colitis. J Patient Rep Outcomes. 2019;3(1):66.","journal-title":"J Patient Rep Outcomes."},{"issue":"6","key":"776_CR29","doi-asserted-by":"publisher","first-page":"813","DOI":"10.17219\/acem\/68986","volume":"27","author":"PW Petryszyn","year":"2018","unstructured":"Petryszyn PW, Paradowski L. Stool patterns and symptoms of disordered anorectal function in patients with inflammatory bowel diseases. Adv Clin Exp Med. 2018;27(6):813\u20138.","journal-title":"Adv Clin Exp Med"},{"key":"776_CR30","unstructured":"China IBD blue paper: Report on the cognition and quality of life of Chinese doctors and patients regarding inflammatory bowel disease. https:\/\/www.fxbaogao.com\/detail\/4927392. Accessed Aug 2025."},{"issue":"1","key":"776_CR31","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s41687-022-00522-2","volume":"6","author":"MC Dubinsky","year":"2022","unstructured":"Dubinsky MC, Shan M, Delbecque L, Lissoos T, Hunter T, Harding G, et al. Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis. J Patient Rep Outcomes. 2022;6(1):114.","journal-title":"J Patient Rep Outcomes."},{"issue":"1","key":"776_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otae001","volume":"6","author":"MD Long","year":"2024","unstructured":"Long MD, Schreiber S, Hibi T, Gibble TH, Fisher DA, Park G, et al. Association of bowel urgency with quality-of-life measures in patients with moderately-to-severely active ulcerative colitis: results from phase 3 LUCENT-1 (induction) and LUCENT-2 (maintenance) studies. Crohn\u2019s Colitis 360. 2024;6(1):otae001.","journal-title":"Crohn's Colitis 360"},{"key":"776_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2025-001838","author":"M Chaparro","year":"2025","unstructured":"Chaparro M, Panaccione R, Sands BE, Irving PM, Goetsch M, Kunina E, et al. Etrasimod for the symptomatic relief of ulcerative colitis: a post-hoc analysis from the ELEVATE UC clinical programme. BMJ Open Gastroenterol. 2025. https:\/\/doi.org\/10.1136\/bmjgast-2025-001838.","journal-title":"BMJ Open Gastroenterol"},{"issue":"23","key":"776_CR34","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462\u201376.","journal-title":"N Engl J Med"},{"issue":"12","key":"776_CR35","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","volume":"19","author":"B Oronsky","year":"2017","unstructured":"Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017;19(12):991\u20131002.","journal-title":"Neoplasia"},{"issue":"6","key":"776_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13309","volume":"35","author":"A Rinke","year":"2023","unstructured":"Rinke A, Ambrosini V, Dromain C, Garcia-Carbonero R, Haji A, Koumarianou A, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours. J Neuroendocrinol. 2023;35(6):e13309.","journal-title":"J Neuroendocrinol"},{"issue":"12","key":"776_CR37","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1136\/annrheumdis-2015-207841","volume":"74","author":"KL Winthrop","year":"2015","unstructured":"Winthrop KL, Novosad SA, Baddley JW, Calabrese L, Chiller T, Polgreen P, et al. Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann Rheum Dis. 2015;74(12):2107\u201316.","journal-title":"Ann Rheum Dis"}],"updated-by":[{"DOI":"10.1007\/s40259-026-00793-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000}}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00776-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00776-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00776-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:45:48Z","timestamp":1783403148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00776-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["776"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00776-y","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"22 March 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: Fig 3 has been updated.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40259-026-00793-x","URL":"https:\/\/doi.org\/10.1007\/s40259-026-00793-x","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dan Tang, Jiao Yu, and Chenxi Qian are employees and stockholders of Eli Lilly and Company; all other authors have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All trial protocols were approved by institutional review boards at each study centre, the primary approval was provided by Shanghai Jiaotong University School of Medicine Renji Hospital Ethics Committee (\u4ec1\u6d4e\u4f26\u5ba1\u30102019\u3011002\u53f7) and the trials were conducted in accordance with the principles outlined in the Declaration of Helsinki and the Council of International Organizations of Medical Sciences international ethical guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients gave written, informed consent before participating in the trials.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Lilly provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available upon reasonable request 6 months after the indication studied has been approved in the USA and EU and after primary publication acceptance, whichever is later. No expiration date of data requests is currently set once data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, and blank or annotated case report forms, will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at\n                      \n                      .","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. Zhihua Ran, Yan Chen, Yinglei Miao, Yufang Wang, Xiang Gao, Jie Zhong, Xueli Ding, Chengdang Wang, Xiaolan Zhang, Yijuan Ding, Naizhong Hu, and Jun Shen contributed to acquisition of data. Substantial contributions to interpretation and review of data were provided by all authors. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contribution"}}]}}